China Biotech Innovation ETF

Reasons to Consider CHB

High Growth Potential

The China biotech market was valued at nearly $40bn in 2021. Forecasts suggest it could surpass $100bn by 2026, highlighting the substantial room for growth.1

Structural Tailwinds

Health care expenditures in China have grown at an annualized rate of 20% since 2003.2 We believe biotech companies are well-positioned to benefit from further growth in this sector.

Targeted Exposure

In contrast to other funds that offer global or broader health care sector exposure, CHB specifically targets the biotech industry in China.

1Research and Markets, Oct 2022
2Council on Foreign Relations, May 2021

Key Information As of 03/21/23

Inception Date 09/22/20
Total Expense Ratio 0.65%
Net Assets $2.52 million
NAV $9.33
Fact Sheet

ETF Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

ETF Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Trading Details As of 03/21/23

Ticker CHB
Bloomberg Index Ticker SOLCHB
CUSIP 37954Y251
ISIN US37954Y2515
Primary Exchange Nasdaq
Shares Outstanding 270,000
Number of Holdings 26
30-Day Median Bid-Ask Spread 1.40%

Distributions As of 03/21/23

30-Day SEC Yield 0.34%
Distribution Frequency Semi-Annually

ETF Prices As of 03/21/23

NAV $9.33 Daily Change $0.32 3.55%
Market Price $9.37 Daily Change $0.31 3.42%

Performance History

As of recent
As of recent
Fund NAV Market Price Index
1 Year -33.21% -33.91% -32.74%
Since Inception -18.05% -18.65% -17.50%
1 Year -19.41% -19.03% -18.82%
Since Inception -16.35% -16.25% -15.80%
Year-to-Date -33.21% -33.91% -32.74%
1 Month -1.03% -3.38% -0.97%
3 Months 12.44% 12.28% 12.60%
Since Inception -36.40% -37.46% -35.43%
Year-to-Date 1.77% 3.82% 1.87%
1 Month -6.97% -5.87% -6.97%
3 Months 0.72% 0.31% 0.89%
Since Inception -35.27% -35.07% -34.22%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 03/21/23

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
9.89 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 6.26 39,750 248,990.00
8.02 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 5.48 36,900 202,071.36
7.88 300122 C2 CHONGQING ZHIF-A BD5CJY8 13.15 15,100 198,522.88
7.59 000661 C2 CHANGCHUN HIGH-A BD5CDB3 24.67 7,747 191,155.72
7.55 1093 HK CSPC PHARMACEUTI 6191997 1.04 183,000 190,077.17
5.30 002252 C2 SHANGHAI RAAS -A BD5CPJ5 0.88 150,900 133,488.42
5.28 002422 C2 SICHUAN KELUN-A BD5CL08 4.06 32,700 132,854.81
5.20 ZLAB ZAI LAB LTD-ADR BD9GVY0 32.50 4,029 130,942.50
5.06 002007 C2 HUALAN BIOLOGI-A BD5CL19 3.10 41,100 127,520.54
4.33 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 2.49 43,850 109,086.41
4.06 300601 C2 SHENZHEN KANGT-A BFY8HT2 4.69 21,793 102,311.73
4.06 002030 C2 DAAN GENE CO LTD-A BD5CKW3 2.27 45,080 102,282.66
3.81 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 8.61 11,138 95,907.48
3.63 1530 HK 3SBIO INC BY9D3L9 1.03 89,000 91,421.07
3.25 603127 C1 JOINN LABORATO-A BK94819 7.87 10,404 81,925.07
2.25 300841 C2 CHENGDU KANGHU-A BMXVCN0 13.65 4,150 56,664.75
2.18 000403 C2 PACIFIC SHUANG-A BMQ8TB5 3.20 17,100 54,769.88
2.04 300482 C2 GUANGZHOU WOND-A BFY8GZ1 4.54 11,300 51,326.70
1.81 9966 HK ALPHAMAB ONCOLOGY BL6WGG4 2.01 22,700 45,535.68
1.29 002038 C2 BEIJING SL -A BD5CJD7 1.29 25,200 32,468.42
1.27 603392 C1 BEIJING WANTAI-A BMXTWX4 17.66 1,815 32,058.80
1.02 603387 C1 GETEIN BIOTECH INC-A BFB4S90 1.97 13,020 25,626.38
0.95 688185 C1 CANSINO BIOLOGICS INC-A BMD9JD3 17.50 1,366 23,905.77
0.91 688317 C1 SHANGHAI ZJ BI-A BQ3RXD3 4.53 5,037 22,820.46
0.79 688526 C1 WUHAN KEQIAN B-A BQ3RXJ9 3.91 5,076 19,826.66
0.54 9939 HK KINTOR PHARMACEUTICAL LTD BMDWVN6 1.05 12,800 13,490.77
0.06 CASH 1.00 1,435 1,434.88
Holdings are subject to change. "Cash" denotes U.S. dollars.

ETF Characteristics As of 03/21/23

Return on Equity 12.30%
Weighted Avg. Market Cap 9,777 M
2022 2023
Price-to-earnings 39.80 27.32
Price-to-book value 3.50 3.21

Source: AltaVista Research, LLC

ETF Risk Stats As of 02/28/23

Versus Beta
S&P 500 0.34
MSCI Emg. Mkts 0.84
Standard Deviation 30.40%

Source: AltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Back to Top